A randomised, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of subcutaneous doses of ACV1 in patients with neuropathic sciatic pain

Trial Profile

A randomised, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of subcutaneous doses of ACV1 in patients with neuropathic sciatic pain

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs ACV 1 (Primary)
  • Indications Neuropathic pain; Sciatica
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Calzada
  • Most Recent Events

    • 17 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top